Loading…
Neurogene Inc. is projected to rise to $44.56 by 2027, a +35% move from its current price of $32.89. NGNE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $31.80 | $32.92 | $34.08 | +0.09% |
| Aug 3 | $31.37 | $32.95 | $34.60 | +0.17% |
| Aug 4 | $31.06 | $32.98 | $35.01 | +0.26% |
| Aug 5 | $30.80 | $33.00 | $35.37 | +0.35% |
| Aug 6 | $30.57 | $33.03 | $35.69 | +0.43% |
| Aug 7 | $30.37 | $33.06 | $35.99 | +0.52% |
| Aug 8 | $30.19 | $33.09 | $36.26 | +0.61% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.19 | $33.09 | $36.26 | +0.61% |
| Week 2 | $29.24 | $33.29 | $37.90 | +1.22% |
| Week 3 | $28.58 | $33.49 | $39.25 | +1.83% |
| Week 4 | $28.05 | $33.70 | $40.47 | +2.45% |
| Week 5 | $27.62 | $33.90 | $41.61 | +3.07% |
| Week 6 | $27.25 | $34.11 | $42.69 | +3.70% |
| Week 7 | $26.93 | $34.31 | $43.73 | +4.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Neurogene Inc. is a clinical stage biotechnology company that develops genetic medicines for rare neurological diseases. Its product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
The company was founded in 2018 and is headquartered in New York, New York. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University.
Neurogene Inc. (NGNE) is a biotechnology company focused on genetic medicines for rare neurological diseases. The stock is currently trading at $33.22 per share, with a market cap of $662.75M, and it ranks 2707.
The near-term outlook reflects a bullish sentiment with multi-year upside evident in the forecast path, including a 2030 average near $68.39 and a substantial long-run trajectory.
A major floor 41.4% below — a decisive break under it would weaken the trend.
The nearest floor, 8.6% below — buyers have tended to step in here.
The nearest ceiling, 30.3% above — a clean break opens room to run.
A major ceiling 46.1% above — clearing it would confirm fresh momentum.
Key NGNE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NGNE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $33.60 | Sell | $33.71 | Sell |
| MA 10 | $34.86 | Sell | $34.56 | Sell |
| MA 20 | $36.47 | Sell | $34.85 | Sell |
| MA 50 | $32.18 | Buy | $32.78 | Buy |
| MA 100 | $28.39 | Buy | $29.67 | Buy |
| MA 200 | $25.27 | Buy | $26.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.99 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -113.18 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.79 | Sell |
| ROC (12) | -16.63 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.48 | Buy |
| Awesome (5,34) | -0.77 | Sell |
| Ultimate (7,14,28) | 20.12 | Buy |
| Momentum (10) | -4.42 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 32.76 | Buy |
| ADX (14) | 14.70 | Neutral |
| ATR (14) | 1.03 | Info |
The 30-day technical picture shows a bullish bias with RSI(14) at 50. The 50-day simple moving average is $31.78 and the 200-day simple moving average is $25.14. Key near-term levels are a support at $29.00 and resistance at $42.84. The 30-day price range spans from $25.67 to $42.99, and annualized volatility is 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.37 | $32.89 | $46.56 | 0% | Neutral | |
| $34.67 | $44.56 | $61.05 | +35% | Bullish | |
| $34.82 | $46.43 | $66.61 | +41% | Bullish | |
| $41.72 | $57.37 | $85.27 | +74% | Bullish | |
| $49.59 | $70.08 | $107.29 | +113% | Bullish | |
| $62.59 | $90.68 | $142.44 | +176% | Bullish | |
| $78.66 | $116.64 | $187.47 | +255% | Bullish | |
| $84.62 | $128.28 | $210.48 | +290% | Bullish | |
| $92.86 | $143.76 | $240.39 | +337% | Bullish | |
| $98.00 | $154.82 | $263.45 | +371% | Bullish | |
| $171.22 | $296.87 | $543.35 | +803% | Bullish | |
| $299.34 | $612.90 | $1,245.55 | +17.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $16.37 | $32.89 | $40.06 | +0.00% |
| September 2026 | $29.16 | $34.78 | $42.85 | +5.75% |
| October 2026 | $29.58 | $35.59 | $44.43 | +2.32% |
| November 2026 | $29.18 | $35.35 | $44.61 | -0.65% |
| December 2026 | $29.97 | $36.54 | $46.56 | +3.36% |
Click any year to see its month-by-month NGNE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NGNE to range from $16.37 to $46.56 through 2026. The $32.89 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The NGNE price prediction for 2027 points to an average of $44.56 (low $34.67, high $61.05) — a potential gain of +35% on today's $32.89. Momentum favours further upside here.
In 2028, NGNE is projected to trade between $34.82 and $66.61, averaging $46.43 — a potential gain of +41% from today's $32.89. That is up +4% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Neurogene Inc.'s 2029 outlook centres on $57.37, within a $41.72 to $85.27 range. That is up +24% on the projected 2028 average. That marks a +74% change versus current levels. Momentum favours further upside here.
By 2030, NGNE could reach as high as $107.29, with a base case around $70.08 and support toward $49.59 — roughly +113% from $32.89. Buyers look set to stay in control over this stretch.
Expect NGNE to range from $62.59 to $142.44 through 2031. The $90.68 average target implies a +176% move from current prices. That is up +29% on the projected 2030 average. Momentum favours further upside here.
The NGNE price prediction for 2032 points to an average of $116.64 (low $78.66, high $187.47) — a potential gain of +255% on today's $32.89. Buyers look set to stay in control over this stretch.
In 2033, NGNE is projected to trade between $84.62 and $210.48, averaging $128.28 — a potential gain of +290% from today's $32.89. That is up +10% on the projected 2032 average. Momentum favours further upside here.
Neurogene Inc.'s 2034 outlook centres on $143.76, within a $92.86 to $240.39 range. That is up +12% on the projected 2033 average. That marks a +337% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, NGNE could reach as high as $263.45, with a base case around $154.82 and support toward $98.00 — roughly +371% from $32.89. Momentum favours further upside here.
Expect NGNE to range from $171.22 to $543.35 through 2040. The $296.87 average target implies a +803% move from current prices. That is up +92% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The NGNE price prediction for 2050 points to an average of $612.90 (low $299.34, high $1,245.55) — a potential gain of +17.6x on today's $32.89. Momentum favours further upside here.
Investing $1,000 in NGNE today (≈ 30.404378 NGNE) could be worth
$18,634.79
+$17,634.79 (+1763%) by 2050 · US Dollar
Based on the average projected NGNE price of $612.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NGNEwould be worth at today's price.
$1,000 invested in NGNE on Jul 31, 2025 (≈ 45.934772 NGNE) would be worth
$1,510.79
+$510.79 (+51.1%) today · 1.51× · US Dollar
Based on a NGNE entry price of $21.77 vs. today's $32.89.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $34.9 | $942.41 | -5.8% |
| 1 month ago | $33.88 | $970.78 | -2.9% |
| 3 months ago | $26.85 | $1,224.95 | +22.5% |
| 6 months ago | $18.33 | $1,794.33 | +79.4% |
| 1 year ago | $21.77 | $1,510.79 | +51.1% |
| All time (5.0y) ago | $143.6 | $229.04 | -77.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NGNE forecast.
Our base-case forecast reaches $66.00 around 2030.
Implied market cap at $66.00: $1.32B
The multi-year forecast shows a clear bullish trajectory, with the average price rising from year to year and strong upside potential. In 2026 the avg is $33.22 with a neutral sentiment and 0% ROI. By 2027 the avg rises to $44.76 (ROI 34.7%), and by 2028 to $45.32 (ROI 36.4%).
In 2029 the avg is $56.50 (ROI 70.1%), and in 2030 the avg is $68.39 (ROI 105.9%). The forecast continues to 2031–2050 with bullish sentiment, including 2040 avg $290.49 (ROI 774.5%) and 2050 avg $590.03 (ROI 1676.1%). Min/Max values accompany each year’s avg, illustrating substantial upside potential alongside notable variability.
Tap a question to reveal the answer.
In 2030 the forecast shows an avg of $68.39 with a max of $108.01 and a min of $46.95, corresponding to a ROI of 105.9% and a bullish sentiment.
The forecast path is shown as bullish from 2027 onward, with the 2030 avg at $68.39 and ROI at 105.9%, and the 2050 avg at $590.03 with ROI 1676.1%, though near-term Year 2026 is neutral with an avg of $33.22 and ROI 0%.
Yes. The 2030 max is $108.01, which crosses the $100 level, while the 2029–2035 range also shows higher potential with higher max values in later years.
Current price is $33.22 and market cap is $662.75M. The stock rank is 2707.
The 30-day range is $25.67 to $42.99.
Neurogene Inc. Community Discussion
0Share your Neurogene Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.